Handbook of Contemporary Neuropharmacology, 3 Volume Set
David R. Sibley (Editor-in-Chief), Israel Hanin (Associate Editor), Michael Kuhar (Associate Editor), Phil Skolnick (Associate Editor)

Hardcover ISBN: 978-0-471-66053-8 March 2007 $1,144.00

DESCRIPTION

Written and edited by recognized experts, this comprehensive reference is also available online via Wiley InterScience.

- Provides a readily accessible reference for students, professionals and libraries alike.

- Editors are recognized authorities in the neuropharmacology and science field.

- Comprehensive reference text for active junior and senior neurobiologists.

- Fills an important niche as a text between research publications and clinical applications.

The Handbook of Contemporary Neuropharmacology is an invaluable resource for principal investigators and working scientists in academia, government and industry. This three volume set it also of interest for academic physicians, postdoctoral fellows and residents, and all high-level graduate students.

ABOUT THE AUTHOR

DAVID R. SIBLEY, PhD, is a Senior Investigator and Chief of the Molecular Neuropharmacology Section in the National Institute of Neurological Disorders and Stroke, National Institutes of Health. His laboratory is currently investigating the molecular, cellular, and biochemical properties of dopamine receptors and their role in neuronal signaling and pathophysiological states.
ISRAEL HANIN, PhD, is Professor and Chair Emeritus in the Department of Pharmacology at Loyola University Chicago. He formerly worked at the National Institute of Mental Health, Laboratory of Preclinical Pharmacology, and at the University of Pittsburgh Department of Psychiatry. Dr. Hanin’s research has focused on cholinergic mechanisms, animal models for Alzheimer’s disease, and the potential role of glycosaminoglycans in the treatment of Alzheimer’s disease.

MICHAEL KUHAR, PhD, is currently a Candler Professor and Georgia Research Alliance Professor of Neuropharmacology at the Yerkes Primate Center at Emory University. He previously was a professor in the Neuroscience Department at Johns Hopkins, and a branch chief at the National Institute on Drug Abuse. Dr. Kuhar has published more than 800 articles, abstracts, book chapters, reviews, and patents.

PHIL SKOLNICK, PhD, D.Sc. (hon.), is Executive Vice President and Chief Scientific Officer for DOV Pharmaceutical, Inc. He was formerly a Lilly Fellow in Neuroscience and also served as Chief of the Laboratory of Neuroscience, National Institutes of Health.

For additional product details, please visit https://www.wiley.com/en-us